F2-Isoprostanes Are Associated With Increased Fracture Risk in Type 2 Diabetes
Plasma F2-isoprostanes levels in individuals with diabetes are associated with increased incident clinical fracture risk independently of baseline BMD.
Authors
- Ann V. Schwartz (ORCID: https://orcid.org/0000-0003-4529-1641)
- Susan K. Ewing (ORCID: https://orcid.org/0000-0003-1153-828X)
- Ruban Dhaliwal (ORCID: https://orcid.org/0000-0003-4179-4006)
- Deepak Vashishth (ORCID: https://orcid.org/0000-0001-5712-0167)
- Bowen Wang (ORCID: https://orcid.org/0000-0003-0049-1623)
Institutions
- Rensselaer Polytechnic Institute (US)
- University of California, San Francisco (US)
- The University of Texas Southwestern Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1210/clinem/dgae788
- Primary Topic
- Eicosanoids and Hypertension Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Norges Idrettshøgskole
- National Institutes of Health
- National Institute on Aging
- National Institute of Nursing Research